GOTHENBURG, Sweden: Astra Tech has today presented new clinical data confirming the clinical effectiveness of its dental implant system. The results gathered through the company’s global research programme demonstrate almost 100 per cent survival rates for the company’s OsseoSpeed implants in sites like the posterior mandible.

Recent multicentre studies have also demonstrated the safety and predictability of OsseoSpeed 3 mm narrow implants and OsseoSpeed Profile implants, company officials said at the Astra Tech World Congress in Gothenburg.

The corporate event, which is being held from Wednesday to Saturday, has drawn international researchers and experts from the field of dental implantology to the company’s headquarters in Sweden. With hundreds of presentations on offer, Astra Tech aims for 3,000 dental professionals to participate in the annual event, which will discuss the future of osseointegration, among other topics.

Since 2011, Astra Tech has been part of DENTSPLY, a US dental company that manufactures and distributes the ANKYLOS and XiVE implant systems through its German-based subsidiary DENTSPLY FRIADENT. DENTSPLY’s CEO, Bret Wise, who attended the meeting on Friday, said that these implants, together with Astra Tech’s recently acquired OsseoSpeed implants, complement the company’s portfolio, as they are for different indications.

Wise also confirmed that OsseoSpeed implants will be distributed and further developed in the future, the German online dental news portal ZWP Online reported.